Manfred Jung spends much of his time researching Biochemistry, Histone deacetylase, Histone, NAD+ kinase and Histone methyltransferase. His research in Enzyme, Enzyme inhibitor, Sirtuin, Group III Histone Deacetylases and Docking are components of Biochemistry. His study focuses on the intersection of Histone deacetylase and fields such as Hydroxamic acid with connections in the field of Growth inhibition and Western blot.
His Histone research focuses on Transcription and how it connects with Zinc, Sirtuin 1 and Protein deacetylase. The study incorporates disciplines such as Phenotype, Cell, Small molecule and Yeast in addition to NAD+ kinase. The concepts of his Histone methyltransferase study are interwoven with issues in Cancer, Methyltransferase and Histone methylation.
His primary scientific interests are in Biochemistry, Histone, Histone deacetylase, Epigenetics and Cancer research. Enzyme, NAD+ kinase, Sirtuin, Docking and In vitro are subfields of Biochemistry in which his conducts study. His Histone research also works with subjects such as
Histone deacetylase is closely attributed to Hydroxamic acid in his research. His Epigenetics research includes themes of Computational biology, Drug discovery and Cell biology. The various areas that he examines in his Cancer research study include Vorinostat, Cell culture, Leukemia and Histone deacetylase inhibitor.
His main research concerns Epigenetics, Biochemistry, Cell biology, Combinatorial chemistry and Histone. His Epigenetics research is multidisciplinary, incorporating elements of Drug action and Cancer research. His biological study spans a wide range of topics, including Triazole, Moiety and Sirtuin.
His research integrates issues of In vitro, Acetylation, Targeted drug delivery, Derivatization and Photoisomerization in his study of Histone. His Acetylation study deals with HDAC6 intersecting with Structure–activity relationship, Docking and HDAC8. As a part of the same scientific study, Manfred Jung usually deals with the Entinostat, concentrating on Albendazole and frequently concerns with Histone deacetylase.
His primary scientific interests are in Epigenetics, Regulation of gene expression, Cell biology, Biochemistry and Cancer research. His studies in Epigenetics integrate themes in fields like Autophagy, In vitro, Acetylation, Histone and Drug discovery. His study in the fields of Histone Demethylases under the domain of Histone overlaps with other disciplines such as Deferasirox.
As a part of the same scientific family, Manfred Jung mostly works in the field of Cell biology, focusing on Methylation and, on occasion, Prostate cancer and Histone H4. His research in Biochemistry intersects with topics in Drug detection and Phenothiazine. Manfred Jung interconnects Transcription factor, IRF8 and Conditional gene knockout in the investigation of issues within Cancer research.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
Julia M. Wagner;Björn Hackanson;Michael Lübbert;Manfred Jung.
Clinical Epigenetics (2010)
SIRT1 regulates HIV transcription via Tat deacetylation.
Sara Pagans;Angelika Pedal;Brian J North;Katrin Kaehlcke.
PLOS Biology (2005)
Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy
Ludovica Morera;Michael Lübbert;Manfred Jung.
Clinical Epigenetics (2016)
Inhibitors of Histone Deacetylase as New Anticancer Agents
Manfred Jung.
Current Medicinal Chemistry (2001)
Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation.
Manfred Jung;Gerald Brosch;Doris Kölle;Hans Scherf.
Journal of Medicinal Chemistry (1999)
Selective Sirt2 inhibition by ligand-induced rearrangement of the active site.
Tobias Rumpf;Matthias Schiedel;Berin Karaman;Claudia Roessler.
Nature Communications (2015)
Structure–Activity Studies on Suramin Analogues as Inhibitors of NAD+‐Dependent Histone Deacetylases (Sirtuins)
Johannes Trapp;Rene Meier;Darunee Hongwiset;Matthias U. Kassack.
ChemMedChem (2007)
HDAC8: a multifaceted target for therapeutic interventions
Alokta Chakrabarti;Ina Oehme;Olaf Witt;Guilherme Oliveira.
Trends in Pharmacological Sciences (2015)
Chemically Induced Degradation of Sirtuin 2 (Sirt2) by a Proteolysis Targeting Chimera (PROTAC) Based on Sirtuin Rearranging Ligands (SirReals)
Matthias Schiedel;Daniel Herp;Sören Hammelmann;Sören Swyter.
Journal of Medicinal Chemistry (2018)
The Emerging Therapeutic Potential of Histone Methyltransferase and Demethylase Inhibitors
Astrid Spannhoff;Astrid Spannhoff;Alexander‐Thomas Hauser;Ralf Heinke;Wolfgang Sippl.
ChemMedChem (2009)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
Martin Luther University Halle-Wittenberg
University of Freiburg
University of Lille
University of Freiburg
University of Freiburg
Buck Institute for Research on Aging
University of Campania "Luigi Vanvitelli"
Goethe University Frankfurt
Innsbruck Medical University
University of Freiburg
New Jersey Institute of Technology
University of Palermo
University of Ulm
Humboldt-Universität zu Berlin
Microsoft (United States)
Duke University
University of Duisburg-Essen
University of Queensland
University of Turku
Grenoble Alpes University
National University of Singapore
University of Fribourg
University of Alabama at Birmingham
Brock University
University of Copenhagen
Iowa State University